Molinalogo

Measure

2022

2023

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

64.90%

Annual Dental Visits (ADV) Total

NB

NB

54.60%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

45.15%

42.63%

46.74%

Appropriate Testing for Pharyngitis (CWP)

62.48%

65.69%

77.56%

Appropriate Treatment for Upper Respiratory Infection (URI) Total

92.74%

91.42%

93.08%

Asthma Medication Ratio (AMR) Total

75.34%

79.69%

69.41%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

67.84%

65.53%

66.19%

Breast Cancer Screening (BCS)

61.03%

60.96%

55.25%

Cervical Cancer Screening (CCS)

63.99%

64.72%

59.85%

Childhood Immunization Status (CIS) Combination #10

42.09%

35.52%

35.04%

Chlamydia Screening in Women (CHL) Total

62.69%

62.88%

61.07%

Controlling High Blood Pressure (CBP)

64.23%

71.29%

65.45%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

81.13%

82.27%

80.86%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

8.93%

19.64%

27.73%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

37.89%

30.95%

46.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

31.99%

41.03%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

13.86%

18.46%

37.31%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

50.00%

62.34%

57.90%

Immunizations for Adolescents (IMA) Combination #2

46.47%

43.07%

38.93%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

5.29%

7.54%

16.94%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

37.56%

34.67%

39.01%

Pharmacotherapy for Opioid Use Disorder (POD) Total

6.33%

10.07%

31.93%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

69.03%

59.35%

75.79%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

87.61%

83.74%

86.93%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

106.31%

101.87%

≤ 92.72%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

91.97%

86.37%

86.86%

Prenatal and Postpartum Care (PPC) Postpartum Care

80.78%

78.10%

80.78%

Prenatal Immunization Status (PRS) Combination Rate

7.04%

8.19%

25.81%

Risk of Continued Opioid Use (COU) 31-Day Total

2.09%

1.95%

≤ 2.45%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

80.48%

81.46%

81.64%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

58.96%

54.48%

73.63%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

75.41%

70.16%

67.07%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

50.41%

49.10%

70.37%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

76.24%

77.50%

63.89%

Use of Imaging Studies for Low Back Pain (LBP)

67.03%

64.30%

75.44%

Use of Opioids at High Dosage (HDO)

13.77%

10.70%

≤ 2.19%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

0.49%

1.11%

≤ 0.870%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

85.40%

84.91%

83.21%